Health ❯ Healthcare ❯ Dermatology
Hidradenitis Suppurativa Melanoma Boils Scabies Psoriasis Inflammatory Skin Diseases Cutaneous Squamous Cell Carcinoma Venous Malformations
The move positions Palvella for faster FDA engagement on a 2026 Phase 2 study targeting a bleeding skin disorder with no approved therapies.
